Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
N
N

Novartis

Balita

Reuters - 18 oras ang nakaraan

Law firm Milberg skirts sanctions over fake claims in credit card fees case

Law firm Milberg skirts sanctions over fake claims in credit card fees case By Mike Scarcella July 15 (Reuters) - A law firm that said it unknowingly submitted fake claims as part of a $5.6 billion antitrust settlement with Visa and Mastercard will escape sanctions for now, a federal magistrate judge has ruled. U.S. Magistrate Judge Joseph Marutollo in Brooklyn said on Saturday that punishing plaintiffs law firm Milberg Coleman Bryson Phillips Grossman was “unnecessary at this time” after th
N
V
Reuters - 23 oras ang nakaraan

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Unilever July 15 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO.HE : The Finnis
B
B
B
B
C
I
M
N
T
T
U
V
B
U
Reuters - 1 araw ang nakaraan

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N
Reuters - 1 araw ang nakaraan

China c.bank seen holding medium-term lending rate steady Monday

RPT-China c.bank seen holding medium-term lending rate steady Monday Repeats story from Friday with no changes to text SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed.
B
N
Reuters - 4 araw ang nakaraan

China c.bank seen holding medium-term lending rate steady Monday

China c.bank seen holding medium-term lending rate steady Monday SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed. While the economy continues to sputter, a weak Chinese currency has remained the key constraint limiting Beijing's monetary easing efforts, as that could further widen the yield gap with oth
B
N
Reuters - 1 linggo ang nakaraan

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds details on fresh job cuts July 9 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO
B
B
B
B
C
I
M
N
T
T
U
V
B
U
Reuters - 2 linggo ang nakaraan

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector COPENHAGEN, July 5 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022. The UK industry body Prescription Medicines Code of Practice Authority (PMCPA) said on Friday that the reprimand followed a voluntary submi
N
P
Reuters - 2 linggo ang nakaraan

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y
Reuters - 2 linggo ang nakaraan

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G
Reuters - 2 linggo ang nakaraan

Judge won't block Mississippi law on discounts for hospitals' contract pharmacies

Judge won't block Mississippi law on discounts for hospitals' contract pharmacies By Brendan Pierson July 1 (Reuters) - A federal judge in Mississippi on Monday refused to block a Mississippi law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
N
Reuters - 3 linggo ang nakaraan

Foreign banks target Switzerland after UBS takeover of Credit Suisse

Foreign banks target Switzerland after UBS takeover of Credit Suisse By Oliver Hirt and Noele Illien ZURICH, June 24 (Reuters) - As Credit Suisse fades into history following its takeover by UBS last year, global banks are expanding in Switzerland to take advantage of companies' desire to spread their business. France's BNP Paribas BNPP.PA , Deutsche Bank DBKGn.DE and U.S.
B
C
D
N
N
U
Reuters - 4 linggo ang nakaraan

Sarepta surges as investors cheer expanded use of gene therapy

UPDATE 2-Sarepta surges as investors cheer expanded use of gene therapy Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13 By Mariam Sunny and Bhanvi Satija June 21 (Reuters) - Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
N
P
T
Reuters - 4 linggo ang nakaraan

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N
Reuters - 4 linggo ang nakaraan

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N
Reuters - 1 buwan ang nakaraan

EU regulator requires secondary cancer risk warning for T therapies

UPDATE 3-EU regulator requires secondary cancer risk warning for CAR-T therapies Changes headline, adds background in paragraphs 3, 5 & 6 June 14 (Reuters) - The European health regulator said on Friday cancer cell therapies known as CAR-T treatments must include a written warning of an associated risk for secondary blood cancers in patients who use them and that patients should be monitored for life.
G
N
Reuters - 1 buwan ang nakaraan

EU regulator mandates label updates on T cancer therapies

EU regulator mandates label updates on CAR-T cancer therapies June 14 (Reuters) - The European health regulator said on Friday product information for a class of cancer therapies known as CAR-T treatments would be required to highlight risk of secondary cancers in patients who use them, ending a five-month safety review. Reporting by Mariam Sunny i
G
N
Reuters - 1 buwan ang nakaraan

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - 1 buwan ang nakaraan

Swiss stocks - Factors to watch on June 10

Swiss stocks - Factors to watch on June 10 ZURICH/GDANSK, June 10(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS * Roche ROG.S - European Commission approves Roche’s Alecensa * Barry Callebaut AG BARN.S - Places New EUR 700 Mln Denominated Bond * Dormakaba Holding AG DOKA.S - To Divest Its Sub-Saharan African Business * Metall Zug AG METN.S , METN.S - Announces Start of JV ANALYSTS' VIEWS BARRY CALLEBAUT AG BARN.S - BERENBERG RAISES TARG
N
N
R
S
Reuters - 1 buwan ang nakaraan

Law firm defends work in $5.6 bln card fee case after disclosing fake claims

Law firm defends work in $5.6 bln card fee case after disclosing fake claims By Mike Scarcella June 7 (Reuters) - A law firm that earlier said it unknowingly submitted fake claims as part of a $5.6 billion settlement with Visa and MasterCard told a U.S. judge on Thursday that other parties had also submitted fraudulent material in the case. Responding to a request for more information from the Brooklyn judge overseeing the antitrust case, New York-founded Milberg Coleman Bryson Phillips Grossman
N
V
Reuters - 1 buwan ang nakaraan

US judge orders probe of Novartis $30 mln settlement claims process

US judge orders probe of Novartis $30 mln settlement claims process By Brendan Pierson June 6 (Reuters) - A federal judge has ordered a probe of the claims distribution process in a $30 million settlement by Novartis NOVN.S with consumers and health plans in an antitrust class action over its hypertension drug Exforge, citing concerns about its integrity.
N

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.